The DOI matches its Crossref record; 83 of the 83 references it cites were found in a registry or an index.
Elesclomol: a copper ionophore targeting mitochondrial metabolism for cancer therapy
Open accessAbstract
Elesclomol is an anticancer drug that targets mitochondrial metabolism. In the past, elesclomol was recognized as an inducer of oxidative stress, but now it has also been found to suppress cancer by inducing cuproptosis. Elesclomol’s anticancer activity is determined by the dependence of cancer on mitochondrial metabolism. The mitochondrial metabolism of cancer stem cells, cancer cells resistant to platinum drugs, proteasome inhibitors, molecularly targeted drugs, and cancer cells with inhibited glycolysis was significantly enhanced. Elesclomol exhibited tremendous toxicity to all three kinds of cells. Elesclomol's toxicity to cells is highly dependent on its transport of extracellular copper ions, a process involved in cuproptosis. The discovery of cuproptosis has perfected the specific cancer suppressor mechanism of elesclomol. For some time, elesclomol failed to yield favorable results in oncology clinical trials, but its safety in clinical application was confirmed. Research progress on the relationship between elesclomol, mitochondrial metabolism and cuproptosis provides a possibility to explore the reapplication of elesclomol in the clinic. New clinical trials should selectively target cancer types with high mitochondrial metabolism and attempt to combine elesclomol with platinum, proteasome inhibitors, molecularly targeted drugs, or glycolysis inhibitors. Herein, the particular anticancer mechanism of elesclomol and its relationship with mitochondrial metabolism and cuproptosis will be presented, which may shed light on the better application of elesclomol in clinical tumor treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Copper induces cell death by targeting lipoylated TCA cycle proteins
Tsvetkov, P., Coy, S., Petrova, B., Dreishpoon, M., Verma, A., Abdusamad, M., Rossen, J., Joesch-Cohen, L., Humeidi, R., Spangler, R. D., et al. (2022) · Science · doi:10.1126/science.abf0529 · Cited by 4,932
Otto Warburg's contributions to current concepts of cancer metabolism
Koppenol, W. H., Bounds, P. L., & Dang, C. V. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3038 · Cited by 3,427
Nasir, O. (2013) · Kidney and Blood Pressure Research · doi:10.1159/000350152 · Cited by 2,331
Glycolysis inhibition for anticancer treatment
Pelicano, H., Martin, D. S., Xu, R.-H., & Huang, P. (2006) · Oncogene · doi:10.1038/sj.onc.1209597 · Cited by 1,516
Proteasome inhibitors: a novel class of potent and effective antitumor agents.
Adams, J., Palombella, V. J., Sausville, E. A., Johnson, J. I., Destree, A. T., Lazarus, D. D., Maas, J., Pien, C. S., Prakash, S., & Elliott, P. J. (1999) · PubMed · Cited by 1,477
Lagadinou, E. D., Sach, A., Callahan, K., Rossi, R. M., Neering, S. J., Minhajuddin, M., Ashton, J. M., Pei, S., Grose, V., O’Dwyer, K. M., et al. (2013) · Cell Stem Cell · doi:10.1016/j.stem.2012.12.013 · Cited by 1,399
Mitochondrial metabolism and cancer
Porporato, P. E., Filigheddu, N., Pedro, J. M. B.-S., Kroemer, G., & Galluzzi, L. (2018) · Cell Research · doi:10.1038/cr.2017.155 · Cited by 1,273
Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function
Viale, A., Pettazzoni, P., Lyssiotis, C. A., Ying, H., Sánchez, N., Marchesini, M., Carugo, A., Green, T., Seth, S., Giuliani, V., et al. (2014) · Nature · doi:10.1038/nature13611 · Cited by 1,259
Niu, B., Liao, K., Zhou, Y., Wen, T., Quan, G., Pan, X., & Wu, C. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.121110 · Cited by 1,168
Roesch, A., Fukunaga-Kalabis, M., Schmidt, E. C., Zabierowski, S. E., Brafford, P. A., Vultur, A., Basu, D., Gimotty, P., Vogt, T., & Herlyn, M. (2010) · Cell · doi:10.1016/j.cell.2010.04.020 · Cited by 1,158
Cited by
Guo, B., Yang, F., Zhang, L., Zhao, Q., Wang, W., Yin, L., Chen, D., Wang, M., Han, S., Xiao, H., et al. (2023) · Advanced Materials · doi:10.1002/adma.202212267 · Cited by 391
Cuproptosis: A novel therapeutic target for overcoming cancer drug resistance
Wang, Y., Chen, Y., Zhang, J., Yang, Y., Fleishman, J. S., Wang, Y., Wang, J., Chen, J., Li, Y., & Wang, H. (2024) · Drug Resistance Updates · doi:10.1016/j.drup.2023.101018 · Cited by 256
Li, Y., Li, J., Zhong, Y., Zhang, Q., Wu, Y., Huang, J., Pang, K., Zhou, Y., Xiao, T., Wu, Z., et al. (2025) · Biomaterials · doi:10.1016/j.biomaterials.2024.122762 · Cited by 25
Metadata
- Authors
- Zheng, P., Zhou, C., Lu, L., Liu, B., & Ding, Y.
- Venue
- Journal of Experimental & Clinical Cancer Research
- Published
- 2022-09-12
- Volume
- 41
- Issue
- 1
- Pages
- 271-271
- ISSN
- 0392-9078 (ISSN-L)
- 1756-9966
- OpenAlex
- W4295517279
- Cited by
- 352
- References
- 83
- FWCI
- 19.47
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Elesclomol: a copper ionophore targeting mitochondrial metabolism for cancer therapy. https://app.cochat.ai/papers/10.1186/s13046-022-02485-0
- The paper
- Zheng, P., Zhou, C., Lu, L., Liu, B., & Ding, Y. (2022). Elesclomol: a copper ionophore targeting mitochondrial metabolism for cancer therapy. Journal of Experimental & Clinical Cancer Research. https://doi.org/10.1186/s13046-022-02485-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.